Welcome to our dedicated page for Core Scientific, Inc./tx SEC filings (Ticker: CORZW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Core Scientific, Inc./tx's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Core Scientific, Inc./tx's regulatory disclosures and financial reporting.
Core Scientific, Inc. received an amended Schedule 13G report from Jane Street entities regarding holdings of its common stock, par value $0.00001 per share. As of June 30, 2026, Jane Street Group, LLC reported beneficial ownership of 20,125,585 Core Scientific shares, representing 6.3% of the outstanding common stock.
All reported shares are held with shared voting and shared dispositive power, and no shares are held with sole voting or dispositive power. Within the group, Jane Street Capital, LLC reported 18,771,563 shares (5.9% of the class), Jane Street Global Trading, LLC reported 1,354,018 shares (0.4%), and Jane Street Singapore Pte. Ltd. reported 4 shares. Jane Street Group, LLC files as the parent holding company for these subsidiaries.
Core Scientific, Inc. officer Todd M. Duchene, Chief Legal and Administrative Officer, reported open-market sales of company common stock. On August 10, 2026, he sold 9,000 shares at a weighted average price of $19.8986 per share and 1,000 shares at a weighted average price of $20.6480 per share. The filing states these transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 5, 2025, and that the prices reflect multiple trades within disclosed ranges.
Kenneth Griffin and affiliated Citadel entities report a significant passive ownership stake in Core Scientific, Inc. Mr. Griffin may be deemed to beneficially own 20,850,479 Shares of Core Scientific common stock, representing 6.5% of the outstanding Shares.
Citadel Securities LLC may be deemed to beneficially own 12,122,241 Shares (3.8%), and Citadel Securities Group LP and Citadel Securities GP LLC each may be deemed to beneficially own 15,649,788 Shares (4.9%). Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC each may be deemed to beneficially own 5,200,691 Shares (1.6%). All reporting persons report no sole voting or dispositive power, but shared voting and dispositive power over their respective blocks. The ownership percentages are based on 321,341,430 Shares outstanding, including 989 Shares issuable upon conversion of certain warrants.
Core Scientific, Inc. reported that Chief Legal and Administrative Officer Todd M. Duchene sold a total of 10,000 shares of common stock on August 3, 2026. The sales occurred in three open market or private transactions at weighted-average prices of $20.3903, $21.55 and $22.6166 per share. All trades were executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, with individual sales taking place within price ranges of $19.99–$20.72, $21.03–$21.95 and $22.12–$22.95 per share.
Core Scientific, Inc. shareholder group including Situational Awareness entities, SAF AI GP, Situational Awareness LLC, Situational Awareness Partners, Leopold Aschenbrenner and Carl Shulman reports beneficial ownership of 14,089,395 shares of common stock, representing 4.4% of the class as of the close of business on August 4, 2026.
They previously may have been deemed to beneficially own 25,608,473 shares, or 8.1% of outstanding common stock, as of July 15, 2026. Percentages are based on 321,340,441 shares outstanding as of July 23, 2026 and 317,885,292 shares outstanding as of May 1, 2026. All reporting persons have shared voting and dispositive power over the reported shares, with no sole voting or dispositive power disclosed.
Adams Mark reported acquisition or exercise transactions in this Form 4 filing.
Core Scientific, Inc. reported that director Mark Adams received a grant of 27,594 restricted stock units of common stock on July 30, 2026. These RSUs vest in two equal installments on July 30, 2027 and July 30, 2028, contingent on his continued service, resulting in direct ownership of 27,594 units.
Core Scientific, Inc. reports that Mark Adams is a director of the company and has filed an initial statement of beneficial ownership on Form 3. The filing lists no reportable transactions or derivative positions and notes an attached Exhibit 24 labeled Power of Attorney.
Core Scientific Inc reports that Vanguard Capital Management has filed a Schedule 13G as a passive owner of its Common Stock. Vanguard Capital Management and certain affiliates beneficially own 16,196,304 shares, representing 5.09% of the outstanding common stock.
Vanguard has sole voting power over 2,398,797 shares and sole dispositive power over 16,196,304 shares, with no shared voting or dispositive power. The holdings include securities held by various Vanguard funds and managed accounts for which Vanguard entities exercise voting and/or dispositive power.
Core Scientific, Inc. (CORZ) Chief Legal and Administrative Officer Todd M. Duchene reported selling a total of 10,000 shares of common stock on July 27, 2026, in three transactions reported as open-market or private sales.
The sales comprised 8,300 shares at $20.7469, 1,600 shares at $21.8925, and 100 shares at $22.4900 per share. The 8,300‑ and 1,600‑share trades were executed at weighted average prices within ranges of $20.47–$21.42 and $21.47–$22.44, respectively. All transactions were effected under a Rule 10b5-1 trading plan adopted on December 5, 2025.
Core Scientific, Inc. appointed Mark W. Adams to its Board of Directors, effective July 29, 2026, increasing the board to seven directors. The board determined he qualifies as an independent director under Sarbanes-Oxley and Nasdaq listing standards and he will receive cash and equity compensation consistent with other non-employee directors.
Adams, age 62, brings extensive technology leadership experience, including roles as President and CEO of Penguin Solutions from 2020 to 2026, CEO of Lumileds from 2017 to 2019, and President of Micron Technology from 2012 to 2016. He also serves on the boards of Seagate Technology and Cadence Design Systems. There are no family relationships or related-party transactions disclosed in connection with his appointment.
Core Scientific designs, builds and operates large-scale, purpose-built data centers for high-density colocation services supporting AI-related workloads and is repurposing remaining digital asset mining facilities to support this colocation business.